Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial
Nutrients · 14.03.2023 · 15 (6) · 1402
DOI: 10.3390/nu15061402 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 14.03.2023. Verfasst von Akari Hiraku und 10 weiteren Autor:innen. Beteiligte Einrichtung: Food Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Probiotics. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Morinaga Milk Industry, Co., Ltd..
Abstract (Originalsprache)
Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of Bifidobacterium longum subsp. infantis (B. infantis) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given B. infantis M-63 (n = 56; 1 × 109 CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with B. infantis M-63 significantly increased the relative abundance of Bifidobacterium compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with B. infantis M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with B. infantis M-63 is well tolerated and contributes to the development of Bifidobacterium-predominant gut microbiota during a critical developmental phase in term infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Food Ingredients and Technology Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan.
- Department of Pediatrics, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, Japan.
- Next Generation Science Institute, R & D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan.
- Department of neurosurgery, Matsumoto City Hospital, 4417-180, Hata, Matsumoto 390-1401, Japan.
ORCID-Profile: Toshitaka Odamaki
Förderung
- Morinaga Milk Industry, Co., Ltd.
Zitieren
APA
Hiraku, A., Nakata, S., Murata, M., Xu, C., Mutoh, N., Arai, S., Odamaki, T., Iwabuchi, N., Tanaka, M., Tsuno, T., & Nakamura, M. (2023). Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial. Nutrients, 15(6), 1402. https://doi.org/10.3390/nu15061402
Vancouver
Hiraku A, Nakata S, Murata M, Xu C, Mutoh N, Arai S, et al. Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial. Nutrients. 2023;15(6):1402. doi:10.3390/nu15061402
BibTeX
@article{Hiraku2023,
author = {Hiraku, Akari and Nakata, Setsuko and Murata, Mai and Xu, Chendong and Mutoh, Natsumi and Arai, Satoshi and Odamaki, Toshitaka and Iwabuchi, Noriyuki and Tanaka, Miyuki and Tsuno, Takahisa and Nakamura, Masahiko},
title = {Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {6},
pages = {1402},
doi = {10.3390/nu15061402}
}
EUVIMED